scholarly journals Expression Pattern of Major Poly C Binding Protein (Pcbp) Isoforms in Cancer Cell Lines of Cervix, Melanoma and Muscle

2019 ◽  
Vol 16 (3) ◽  
pp. 537-543
Author(s):  
Gargi Ghosh ◽  
Utpal Basu
Keyword(s):  
Expression Pattern ◽  
Cell Lines ◽  
Cancer Cell ◽  
Rna Binding ◽  
Rna Virus ◽  
Binding Protein ◽  
Cancer Cell Lines ◽  
Cellular Functions ◽  
Kh Domain ◽  
Post Transcriptional Regulation

Poly (C) binding proteins (PCBPs) are members of sequence specific RNA binding protein family with conserved KH domain. There are four identified isoforms such as Pcbp1 or α-CP1 (α-Complex proteins), Pcbp2 or α-CP2, Pcbp3 or α-CP3 and Pcbp4 or α-CP4. Among them Pcbp1 and Pcbp2 are the most studied and found to be associated with various cellular functions such as transcriptional regulations, translational regulations and mRNA stability. Although two proteins share extensive similarity, they differ in function and localization. Pcbp1 has role in tumorigenesis, and metastasis, which are key phenomena of cancer. Role of pcbp2 has been well documented in the biology of RNA virus, namely translation and replication. Here, we studied expression pattern of Pcbp1 and Pcbp2 in three different cancer cell lines namely HeLa, RD, and A375 originated from different tissues. The results indicate not only differential abundance of these two proteins in three cell lines, but also discordant expression of pcbp1 in mRNA and protein level in three cell lines. The study therefore suggests post-transcriptional regulation of pcbp1 expression in these cell lines.

Variances in the Expression Profile of the EMT-Related Genes in Endometrial Cancer Lines In Vitro Study

2021 ◽  
Vol 22 ◽  
Author(s):  
Robert Nowakowski ◽  
Beniamin Grabarek ◽  
Anna Burnat-Olech ◽  
Dariusz Boroń ◽  
Monika Paul-Samojedny
Keyword(s):  
Endometrial Cancer ◽  
Expression Pattern ◽  
Cell Lines ◽  
Cancer Cell ◽  
Cell Cultures ◽  
Expression Profile ◽  
Histological Grade ◽  
Cancer Cell Lines ◽  
Endometrial Cancer Cell

Background: This study aimed to evaluate the variances in the expression pattern of mRNAs and miRNAs related to the EMT in the Ishikawa (histological grade 1; G1), EC-1A (histological grade 2; G2), and KLE (histological grade 3; G3) cell cultures under cisplatin treatment. Methods: Endometrial cancer cell lines were exposed to 75.22 mg (an average concentration of the drug used in patients with endometrial cancer) for 12.24 and 48 hours compared to the untreated cells (control). The molecular analysis included extraction of total RNA, microarray analysis (mRNA and miRNA), RTqPCR, and the ELISA assay. Results: Out of 226 mRNAs associated with the EMT, the number of mRNAs differentially expressed in endometrial cancer cell cultures treated with cisplatin compared to a control culture was as follows: Ishikawa line - 87 mRNAs; EC-1A - 84 mRNAs; KLE - 71 mRNAs (p<0.05). The greatest changes in the Ishikawa line treated with the drug compared to the control were noticed for mRNA STAT1 TGFβ1, SMAD3, FOXO8, whereas in EC-1A, they were mRNA TGFβ1, BAMBI, SMAD4, and in KLE mRNA COL1A1, FOXO8, TGFβ1. The analysis also showed that miR-106a, miR-30d, miR-300 are common for all cell lines used in this experiment. Conclusion: Cisplatin changes the expression profile of genes associated with EMT in endometrial cancer cell lines. It seems that the expression pattern of TGFβ1 might be a promising, supplementary molecular marker of the effectiveness of cisplatin therapy. The analysis showed that miR-30d, miR-300, and miR-106a are involved in the regulation of the expression of EMT-related genes.

Abstract 454: ADAM proteases shed UL-16-binding protein 2 in human lung cancer cell lines.

2013 ◽  
Author(s):  
Kosuke Yamaguchi ◽  
Hiroki Hikumi ◽  
Shinji Matsumaga ◽  
Miyako Takata ◽  
Naoki Kinoshita ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Human Lung ◽  
Binding Protein ◽  
Cancer Cell Lines ◽  
Human Lung Cancer ◽  
Lung Cancer Cell ◽  
Human Lung Cancer Cell

scholarly journals Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines

BMC Cancer ◽  
2010 ◽  
Vol 10 (1) ◽  
Author(s):  
Andrea Schröpfer ◽  
Ulrike Kammerer ◽  
Michaela Kapp ◽  
Johannes Dietl ◽  
Sonja Feix ◽  
...  
Keyword(s):  
Matrix Metalloproteinases ◽  
Expression Pattern ◽  
Cell Lines ◽  
Cancer Cell ◽  
Gynecological Cancer ◽  
Cancer Cell Lines

A gene expression profile indicative of early stage HER2 tyrosine kinase inhibitor response.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e11536-e11536
Author(s):  
Fiona O'Neill ◽  
Stephen F. Madden ◽  
Martin Clynes ◽  
Padraig Doolan ◽  
John Crown ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Tyrosine Kinase ◽  
Cell Line ◽  
Expression Pattern ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines

e11536 Background: Lapatinib, afatinib and neratinib are tyrosine kinase inhibitors (TKIs) of HER2 and EGFR growth receptors. A panel of breast cancer cell lines was treated with these agents and gefintib (EGFR inhibitor) and the expression pattern of a specific panel of genes investigated as a potential marker of early drug response. Methods: RNA was extracted from breast cancer cell lines (BT474, SKBR3 and MDAMB453) with differing HER2 expression patterns and sensitivity to lapatinib before and 12hrs after treatment with 1 µM of lapatinib, 150nM of afatinib, 150nM of neratinib or 1µM of gefitinib. Gene expression changes were measured by Taqman RT-PCR and RQ values were determined using the comparative cycle threshold (Ct) method. Results: The expression of RB1CC1, ERBB3, FOXO3a, NR3C1 was directly correlated with the degree of sensitivity of the cell line to lapatinib and was observed to “switch” from up-regulated to down-regulated in the HER2 expressing lapatinib insensitive cell line (MDAMD453). The CCND1 gene (functionally linked to the other four genes) demonstrated an inversely proportional response to drug exposure; showing a trend of strong down-regulation in lapatinib-sensitive lines. A similar expression pattern was observed following the treatment with both neratinib and afatinib. In contrast, gefitinib treatment, resulted in a completely different expression pattern change. Conclusions: In these HER2-expressing cell models, lapatinib, neratinib and afatinib treatment generated a common, characteristic and specific gene expression response, proportionate to the sensitivity of the cell lines to the HER2 inhibitor. Characterisation of changes in these genes shortly after drug treatment may therefore give a valuable predictor of the likely extent and specificity of tumour HER2 inhibitor response in patients, potentially guiding more specific use of these agents.

Sign in / Sign up

Export Citation Format

Share Document